Mon, Apr 6, 9:25 AM, Zacks
Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes
Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.
Mon, Apr 6, 9:13 AM, Zacks
Regeneron-Sanofi's Dupixent Data Positive in Atopic Dermatitis
Regeneron (REGN) and Sanofi announce positive detailed data on Dupixent in children aged 6-11 years with uncontrolled severe atopic dermatitis.